CHOC Children’s has gone live with a new learning management tool, Healthstream, that is accessible to all CHOC physicians, non-physician providers and associates who have access to Cerner and CHOCPort. Through Healthstream, you can access modules to help prepare you with the transition to ICD-10.
Please note this important education must be completed by Oct. 1, 2015.
Access to this education is simple. Your login and password is the same as your current active directory password that you use for sign in to CHOCPort and Cerner. The link to Healthstream is http://www.healthstream.com/hlc/CHOC. This link will also be available on remote.choc.org and on PAWS intranet.
Once you are logged in, go to Weblinks, then Healthstream, to access the three brief courses.
For more information or a brief training, please contact Stephanie Murphy, ICD-10 education and training lead at CHOC, at 714-509-3196 or firstname.lastname@example.org.
In this CHOC Children’s grand rounds video, Dr. Neal Nakra, pediatric pulmonologist and medical director of CHOC’s pediatric sleep program, addresses the topic of obstructive sleep apnea (OSA) and obesity in the pediatric population. In addition to discussing the trends in OSA, Dr. Nakra details the relationship between the condition and metabolic syndrome. Data, collected over the past decade, regarding the effects of OSA treatment on components of metabolic syndrome is also highlighted.
After watching this video, viewers should be able to
describe the screening process for OSA;
determine the possible mechanisms underlying the connection between OSA, obesity and metabolic syndrome; and
describe the possible effects of OSA treatment on obesity and metabolic syndrome.
For more information on upcoming clinical events at CHOC, visit www.choc.org/cme.
Recognizing that caring for neonates with life-threatening conditions should be an integral part of education for all health professionals, CHOC Children’s will host the second annual Neonatal Palliative Care Educational Symposium on Oct. 9 from 8 a.m. to 4:30 p.m.
Designed for neonatologists, critical care specialists, pediatricians, pediatric subspecialists, registered nurses and interdisciplinary team, the conference has a comprehensive curriculum that combines interactive panel discussions, role playing, family interviews and formal didactics.
Decisions pertaining to life-sustaining treatment in children with life-threatening illnesses may still prove contentious, difficult and emotive. To that end, the symposium has a handful of goals for attendees:
to improve understanding of the needs of infants and neonates with life-threatening conditions and their families;
to help develop an approach that will be appropriate across different communities;
to provide care that responds adequately to suffering;
to advance strategies that support caregivers and health-care providers; and
to promote needed change by cultivating educational programs.
Acknowledging that end-of-life counseling is an essential component of informed consent and comprehensive communication, Medicare supports plans to reimburse doctors for this service in 2016. This will also entail accountability for education and training, so this conference can help doctors meet any new requirements.
California-licensed physicians are required to take, as a one-time requirement, 12 hours of continuing medical education on pain management and the appropriate care and treatment of the terminally ill. This conference can help new pediatricians to claim this credit in one of the few real-time educational sessions in pediatric palliative care on the West Coast.
Learn more about this conference, including tuition, presenting faculty and other topics to be discussed.
The Hyundai Cancer Institute at CHOC Children’s, under the direction of Dr. Leonard Sender, is a proud partner in the California Kids Cancer Comparison Initiative (CKCC), one of two demonstration projects recently selected by the new California Initiative to Advance Precision Medicine, a public-private effort launched by Governor Edmund G. Brown, Jr. CHOC patients will become the first in the state to benefit from big data bioinformatics.
CKCC will give cancer clinicians access to a much broader pool of genetic data than has been readily available, including tumor sequencing data from children and adults around the world. Through the use of a social media platform that maintains the privacy and security of patients’ data, clinicians and patients can upload, analyze and communicate genomic information and associated data. In addition to CHOC, the project includes investigators from UC Irvine, UC San Francisco, Stanford University, USC, the Pacific Pediatric Neuro-Oncology Consortium, including UCLA and UC San Diego, Children’s Hospital of Philadelphia and the Translational Genomics Research Institute.
CHOC’s key contribution to CKCC centers on the clinical trial “Pilot project: Molecular Profiles of Refractory and Recurrent Childhood, Adolescent and Young Adult Cancer.” Patients, whose cancer is either recurrent (returned after treatment) or refractory (not responding to treatment), have tumor and non-tumor specimens collected and sequenced to identify their molecular profiles. The information helps the care team personalize treatment plans, in addition to providing insight on why some cancers respond to therapy or recur despite treatment. As a result of CHOC’s participation in CKCC, these patients will become the first in California to benefit from big data comparisons based on the large cancer genomic datasets gathered and shared by the participating sites.
“The Hyundai Cancer Institute at CHOC made a commitment 10 years ago to invest time and resources in building a strong infrastructure that supports innovative genomic medicine techniques, and we’ve made tremendous progress. The era of precision medicine is here, and we cannot work in isolation. The richer the data, the richer our insight, helping advance clinical leads and new hope for patients and their families,” says Dr. Sender.
“It is a fundamental right of any individual to be offered fertility preservation,” Dr. Leonard Sender, medical director of the Cancer Institute told the online news site. “If we, as a society, believe in cancer survivorship, then what we need is for people to have a choice as to if they want to have children or not.”
Earlier this year, Dr. Sender co-hosted a workshop on oncofertility at Stupid Cancer’s CancerCon. The goal was to bring together leading experts on fertility preservation to discuss the need and path forward to make fertility preservation a topic of conversation with every AYA oncology patient undergoing treatment at every pediatric hospital in the country.